Shopping Cart
Remove All
Your shopping cart is currently empty
IL-17A Protein, Human, Recombinant V2 is expressed in E. coli. The accession number is Q16552.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 μg | $48 | 7-10 days | 7-10 days | |
| 10 μg | $80 | 7-10 days | 7-10 days | |
| 20 μg | $130 | 7-10 days | 7-10 days | |
| 50 μg | $243 | 7-10 days | 7-10 days | |
| 100 μg | $396 | 7-10 days | 7-10 days | |
| 200 μg | $700 | 7-10 days | 7-10 days | |
| 500 μg | $1,480 | 7-10 days | 7-10 days |
| Biological Activity | Immobilized Human AXL-His at 10μg/ml (100 μl/well) can bind Human GAS6-His*.*: Biotinylated by NHS-biotin prior to testing The ED50 of Recombinant Human GAS6-His* is 0.04466 ug/ml. (Regularly tested) |
| Description | IL-17A Protein, Human, Recombinant V2 is expressed in E. coli. The accession number is Q16552. |
| Species | Human |
| Expression System | E. coli |
| Accession Number | Q16552 |
| Synonyms | interleukin 17A,IL-17A,IL-17,IL17,CTLA-8,CTLA8 |
| Construction | Gly24-Ala155 |
| Protein Purity | > 95% as determined by SDS-PAGE |
| Molecular Weight | 15.26 kDa (Predicted); 16 kDa (Reducing conditions) |
| Endotoxin | < 1.0 EU/μg of the protein as determined by the LAL method. |
| Formulation | Lyophilized from a 0.2 μm filtered solution of 20 mM PB, 150 mM NaCl, pH 7.4. |
| Stability & Storage | Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots. |
| Shipping | In general, Lyophilized powders are shipping with blue ice. Solutions are shipping with dry ice. |
| Research Background | Interleukin-17 is a potent pro-inflammatory cytokine produced by activated memory T cells. There are at least six members of the IL-17 family in humans and in mice. As IL-17 shares properties with IL-1 and TNF-alpha, it may induce joint inflammation and bone and cartilage destruction. This cytokine is found in synovial fluids of patients with rheumatoid arthritis, and produced by rheumatoid arthritis synovium. It increases IL-6 production, induces collagen degradation and decreases collagen synthesis by synovium and cartilage and proteoglycan synthesis in cartilage. IL-17 is also able to increase bone destruction and reduce its formation. Blocking of interleukin-17 with specific inhibitors provides a protective inhibition of cartilage and bone degradation. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.